JP2012051897A - Antibacterial agent, oral cavity composition and food and drink containing the same - Google Patents
Antibacterial agent, oral cavity composition and food and drink containing the same Download PDFInfo
- Publication number
- JP2012051897A JP2012051897A JP2011211692A JP2011211692A JP2012051897A JP 2012051897 A JP2012051897 A JP 2012051897A JP 2011211692 A JP2011211692 A JP 2011211692A JP 2011211692 A JP2011211692 A JP 2011211692A JP 2012051897 A JP2012051897 A JP 2012051897A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- parts
- antibacterial agent
- bamboo
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 239000003242 anti bacterial agent Substances 0.000 title claims abstract description 29
- 210000000214 mouth Anatomy 0.000 title claims description 14
- 235000013305 food Nutrition 0.000 title abstract description 23
- 239000000284 extract Substances 0.000 claims abstract description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 241000235349 Ascomycota Species 0.000 claims abstract description 24
- 241000221198 Basidiomycota Species 0.000 claims abstract description 21
- 244000168667 Pholiota nameko Species 0.000 claims abstract description 5
- 235000014528 Pholiota nameko Nutrition 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 239000003960 organic solvent Substances 0.000 claims abstract description 4
- 241000272503 Sparassis radicata Species 0.000 claims abstract 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 11
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 10
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 10
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 10
- 239000011425 bamboo Substances 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 241000242583 Scyphozoa Species 0.000 claims description 5
- 244000103635 Lyophyllum ulmarium Species 0.000 claims description 4
- 235000015934 Lyophyllum ulmarium Nutrition 0.000 claims description 4
- 241000222518 Agaricus Species 0.000 claims description 3
- 240000001462 Pleurotus ostreatus Species 0.000 claims description 3
- 235000001603 Pleurotus ostreatus Nutrition 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 241001330002 Bambuseae Species 0.000 claims 7
- JFXSGPUFCQCCQM-UHFFFAOYSA-N 1-hydroxy-2-oxopyridine-4-carboxylic acid Chemical group OC(=O)C=1C=CN(O)C(=O)C=1 JFXSGPUFCQCCQM-UHFFFAOYSA-N 0.000 claims 1
- 241000222511 Coprinus Species 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 26
- 208000002925 dental caries Diseases 0.000 abstract description 21
- 208000028169 periodontal disease Diseases 0.000 abstract description 16
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 14
- 241000193987 Streptococcus sobrinus Species 0.000 abstract description 13
- 241000186044 Actinomyces viscosus Species 0.000 abstract description 12
- 241000605986 Fusobacterium nucleatum Species 0.000 abstract description 12
- 241000605862 Porphyromonas gingivalis Species 0.000 abstract description 12
- 241000194019 Streptococcus mutans Species 0.000 abstract description 11
- 241000193996 Streptococcus pyogenes Species 0.000 abstract description 11
- 230000002949 hemolytic effect Effects 0.000 abstract description 8
- 208000025157 Oral disease Diseases 0.000 abstract description 6
- 208000030194 mouth disease Diseases 0.000 abstract description 6
- 206010016952 Food poisoning Diseases 0.000 abstract description 5
- 208000019331 Foodborne disease Diseases 0.000 abstract description 5
- 241000194017 Streptococcus Species 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 240000002769 Morchella esculenta Species 0.000 abstract description 2
- 235000002779 Morchella esculenta Nutrition 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 244000028550 Auricularia auricula Species 0.000 abstract 1
- 235000000023 Auricularia auricula Nutrition 0.000 abstract 1
- 240000005856 Lyophyllum decastes Species 0.000 abstract 1
- 235000013194 Lyophyllum decastes Nutrition 0.000 abstract 1
- 241001138370 Pleurotus pulmonarius Species 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 244000309464 bull Species 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 230000000844 anti-bacterial effect Effects 0.000 description 17
- 239000000469 ethanolic extract Substances 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 239000003205 fragrance Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 241000233866 Fungi Species 0.000 description 8
- 150000001765 catechin Chemical class 0.000 description 8
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 8
- 235000005487 catechin Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229940034610 toothpaste Drugs 0.000 description 6
- 239000000606 toothpaste Substances 0.000 description 6
- 208000002064 Dental Plaque Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 229940094952 green tea extract Drugs 0.000 description 5
- 235000020688 green tea extract Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 231100000676 disease causative agent Toxicity 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002324 mouth wash Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241000186046 Actinomyces Species 0.000 description 3
- 206010006326 Breath odour Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 244000082204 Phyllostachys viridis Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- -1 gummy Substances 0.000 description 3
- 239000002035 hexane extract Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 240000008154 Piper betle Species 0.000 description 2
- 235000008180 Piper betle Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 206010061372 Streptococcal infection Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 229940069780 barley extract Drugs 0.000 description 2
- 210000000476 body water Anatomy 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 235000013736 caramel Nutrition 0.000 description 2
- 150000001782 cephems Chemical class 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000004195 gingiva Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 235000015205 orange juice Nutrition 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 208000002679 Alveolar Bone Loss Diseases 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000003433 Gingival Pocket Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 240000000588 Hericium erinaceus Species 0.000 description 1
- 235000007328 Hericium erinaceus Nutrition 0.000 description 1
- 241000251511 Holothuroidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000019428 Ligament disease Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 240000003889 Piper guineense Species 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 206010044029 Tooth deposit Diseases 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 208000034391 chronic adult periodontitis Diseases 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 201000009241 dentin caries Diseases 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 201000005562 gingival recession Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 208000008655 root caries Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Cosmetics (AREA)
Abstract
Description
本発明は、口腔疾患である虫歯(う蝕)の原因菌とされるストレプトコッカス・ミュータンス(Streptococcus mutans)、ストレプトコッカス・ソブリヌス(Streptococcus sobrinus)や、歯周病の原因菌とされるアクチノマイセス・ビスコサス(Actinomyces viscosus)、ポルフィロモナス・ジンジバリス(Porphyromonas gingivalis)、フゾバクテリウム・ヌクレイタム(Fusobacterium nucleatum)、炎症性起因菌である溶血性連鎖球菌のストレプトコッカス・ピオゲネス(Streptococcus pyogenes)、食中毒の原因菌である黄色ブドウ球菌スタフィロコッカス・アウレウス(Staphylococcus aureus)の増殖を抑制する子嚢菌類及又は担子菌類由来の抽出物を有効成分とする抗菌剤及びそれを含有する口腔用組成物並びに飲食品に関する。 The present invention relates to Streptococcus mutans, Streptococcus sobrinus and Streptococcus sobrinus, which are causative bacteria of dental caries (caries) which are oral diseases, and Actinomyces Actinomyces viscosus, Porphyromonas gingivalis, Fusobacterium nucleatum, Streptococcus pyogenes of Streptococcus pyogenes, the causative agent of inflammation, and the cause of yellow poisoning of food poisoning The present invention relates to an antibacterial agent comprising an extract derived from ascomycetes or basidiomycetes that suppresses the growth of Staphylococcus aureus, an oral composition containing the same, and a food and drink.
口腔内には数百種類もの細菌が存在し、デンタルプラーク、歯肉溝、唾液などでそれぞれ特有の細菌叢を形成して生息し、う蝕や歯周病の原因に密接に関わっている。 Hundreds of types of bacteria are present in the oral cavity, and they are inhabited by forming their own bacterial flora with dental plaque, gingival crevice, saliva, etc., and are closely related to the causes of caries and periodontal disease.
強いう蝕原性を有するミュータンスレンサ球菌(Streptococcus mutans、Streptococcus sobrinus)は飲食物中のスクロースから粘着性のある多糖を合成する。その多糖の中では、ミュータンスレンサ球菌をはじめ種々の細菌が繁殖し、デンタルプラークを形成する。また、ミュータンスレンサ球菌は、種々の糖から乳酸などの有機酸を生成し、デンタルプラーク中に滞留させるので、歯のエナメル質を侵し虫歯を誘発する。歯肉縁上プラーク細菌であるレンサ球菌に次いで数の多いのが放線菌(アクチノマイセス(Actinomyces))を中心としたグラム陽性桿菌ある。アクチノマイセス・ビスコサス(Actinomyces viscosus)はデンタルプラークの構成細菌であると同時に歯石形成に関与しており、根面う蝕、特に深部象牙質う蝕病巣から高い割合で検出される。また、アクチノマイセス・ビスコサス細胞壁成分が主に免疫病理学的傷害作用を起こし、それらが人の歯肉縁に関与していると考えられている。従って、う蝕、歯石の発生を予防するためには、上記したミュータンスレンサ球菌、アクチノマイセス・ビスコサスの増殖を抑制することが最も効果的な方法である。 Streptococcus mutans (Streptococcus sobrinus), which has strong cariogenic properties, synthesizes sticky polysaccharides from sucrose in food and drink. Among the polysaccharides, various bacteria such as mutans streptococci breed and form dental plaques. Moreover, since mutans streptococci produce organic acids such as lactic acid from various sugars and retain them in dental plaque, they invade tooth enamel and induce tooth decay. Next to streptococcus, which is a gingival marginal bacterium, is the gram-positive gonococcus centered on actinomyces. Actinomyces viscosus (Actinomyces viscosus) is a constituent bacteria of dental plaque and is also involved in calculus formation, and is detected in a high proportion from root caries, especially deep dentin caries lesions. In addition, it is considered that Actinomyces viscosus cell wall components mainly cause immunopathological injury and are involved in human gingival margin. Therefore, in order to prevent the occurrence of caries and calculus, the most effective method is to suppress the growth of the above-mentioned mutans streptococci and Actinomyces viscosus.
歯周病は、口臭(悪臭)、歯肉の腫れ/痛みを発生させ、更に悪化すると、歯根膜疾患、歯肉ポケットの発生及び歯槽骨の減損を生じ、歯の動揺/脱落を発生させる。歯周病は、デンタルプラークや歯石を放置しておくことにより発生する。上記プラーク内では健康歯肉の局所細菌叢に比べ成人性歯周炎の病原菌として知られているフゾバクテリウム・ヌクレイタム(Fusobacterium nucleatum)、ポルフィロモナス・ジンジバリス(Porphyromonas gingivalis)等の偏性嫌気性菌の割合が高くなる。またこれらの細菌は口臭の原因物質であるメチルメルカプタンを産生する原因菌であることが知られている。従って、歯周病の発生及び口臭の発生を予防するためには、歯周病菌の増殖を抑制することが最も効果的な方法である。 Periodontal disease causes halitosis (bad odor) and swelling / pain of the gingiva, and when further worsened, causes periodontal ligament disease, gingival pockets and alveolar bone loss, and tooth agitation / loss. Periodontal disease occurs when dental plaque or tartar is left untreated. Percentage of obligate anaerobes such as Fusobacterium nucleatum and Porphyromonas gingivalis that are known as pathogens of adult periodontitis in the plaque compared to the local bacterial flora of healthy gingiva Becomes higher. These bacteria are known to be causative bacteria that produce methyl mercaptan, which is a causative substance of bad breath. Therefore, in order to prevent the occurrence of periodontal disease and bad breath, it is the most effective method to suppress the growth of periodontal disease bacteria.
連鎖球菌感染症は炎症性起因菌である溶血性連鎖球菌のストレプトコッカス・ピオゲネス(Streptococcus pyogenes)が咽頭に進入し発育することにより発症する真皮の瀰漫性炎症であり、乳幼児、高齢者、又は抵抗力の低下した人に多くみられる疾患である。発熱、咽頭炎、扁桃炎、苺舌と菌が産出する外毒素による赤い発疹を認めるものを猩紅熱と呼ぶ。 Streptococcal infection is a diffuse inflammation of the dermis that develops when the inflammatory pathogenic Streptococcus pyogenes enters the pharynx and develops. It is an infant, elderly, or resistant It is a disease that is common in people who have declined. A fever, sore throat, tonsillitis, or a red rash caused by exotoxin produced by tongue and fungus is called scarlet fever.
ブドウ球菌は、鼻腔、皮膚、口腔、消化管などに広く分布する化膿性疾患の主な病原菌である。特に病原性の強いものが黄色ブドウ球菌スタフィロコッカス・アウレウス(Staphylococcus aureus)であり、その生産する腸管毒による食中毒の原因菌ともなる。口腔内においては、う蝕の進行した感染根管や根端病変からの分離率が高い。さらに、顎骨の骨髄炎、耳下腺炎などを起こすことがある。 Staphylococci are the main pathogens of purulent diseases that are widely distributed in the nasal cavity, skin, oral cavity, digestive tract, and the like. A particularly highly pathogenic one is Staphylococcus aureus, which is a causative agent of food poisoning due to the intestinal toxin produced by the staphylococcus aureus. In the oral cavity, the rate of separation from infected root canals and root tip lesions with advanced caries is high. In addition, jawbone osteomyelitis, parotitis, etc. may occur.
さらに近年、口腔細菌が肺炎や心血管系の疾患など多くの全身疾患にも関連されていることが示唆されており(例えば非特許文献1参照)、そのため全身の健康のためにもオーラルケアの必要性が強調されるようになってきた。 In recent years, it has been suggested that oral bacteria are associated with many systemic diseases such as pneumonia and cardiovascular diseases (see Non-Patent Document 1, for example). The need has been emphasized.
ここで、上記のような口腔内疾患及び連鎖球菌感染症、黄色ブドウ球菌に対する従来の治療法について、以下説明する。 Here, conventional treatments for the above oral diseases, streptococcal infections, and Staphylococcus aureus will be described below.
虫歯、歯周病などの口腔病原菌に対する治療用薬剤としては、これらの病原菌の生育を抑制するような殺菌剤又は抗菌性物質の応用が試みられてきた。例えば、クロルヘキシジン、塩化セチルピリジニウム、ポピドンヨード等の殺菌剤やペニシリン類、セフェム類、ニューキノン類、マクロライド系等の抗菌性物質が従来使われてきた。(例えば非特許文献1、2参照)溶血性連鎖球菌症も同様にペニシリン、エリスロマイシン、クリンダマイシン等の抗菌性物質が治療に使用されている。メチシリン、セフェム耐性等の多剤耐性が問題となっている黄色ブドウ球菌で、最も信頼されている抗菌性物質がバンコマイシンである。 As therapeutic agents for oral pathogenic bacteria such as caries and periodontal diseases, application of bactericides or antibacterial substances that suppress the growth of these pathogenic bacteria has been attempted. For example, bactericides such as chlorhexidine, cetylpyridinium chloride, and popidone iodine and antibacterial substances such as penicillins, cephems, new quinones, and macrolides have been used. (For example, see Non-Patent Documents 1 and 2) For hemolytic streptococci, antibacterial substances such as penicillin, erythromycin, and clindamycin are also used for treatment. Vancomycin is the most reliable antibacterial substance in Staphylococcus aureus, which has a problem with multidrug resistance such as methicillin and cephem resistance.
しかしながら、これら抗生物質は、作用が強力であるが、副作用が強く、更にこれらの抗生物質に対する耐性菌が出現する可能性も指摘されており、長期にわたっての使用は困難とされている。他の殺菌剤も抗菌スペクトルがかなり広いことから、高濃度で使用すれば、口腔内の正常細菌叢を乱して、菌交代症などを引き起こす可能性がある一方、低濃度の使用では、病原菌に対する充分な実行が得られないという問題点があった。(例えば非特許文献2、3) However, although these antibiotics have a strong action, they have strong side effects, and it has been pointed out that resistant bacteria against these antibiotics may appear, making it difficult to use for a long time. Other antibacterials also have a fairly broad antibacterial spectrum, so using them at high concentrations can disrupt the normal bacterial flora in the oral cavity and cause fungal substitution, while using low concentrations can cause pathogenic bacteria. There was a problem that sufficient execution was not obtained. (For example, Non-Patent Documents 2 and 3)
このような観点から、日常的に使用出来る抗菌性物質として、比較的作用の温和な植物抽出物や香料成分の応用が種々検討されてきている。食品又は天然物由来の成分で虫歯及び歯周病などの口腔内疾患に効果を有する物として緑茶抽出物(カテキン類)(例えば特許文献1、2、非特許文献4、5参照)、決明子抽出物、車前子抽出物(例えば特許文献3参照)、ハトムギエキス(例えば特許文献4参照)、キンマエキス(例えば特許文献5参照)が知られている。 From such a point of view, various applications of relatively mild plant extracts and perfume ingredients have been studied as antibacterial substances that can be used on a daily basis. Green tea extract (catechins) (see, for example, Patent Documents 1 and 2 and Non-Patent Documents 4 and 5) as a product derived from foods or natural products and having an effect on oral diseases such as caries and periodontal disease. A thing, a car anterior extract (for example, refer patent document 3), a barley extract (for example, refer patent document 4), and a betel extract (for example, refer patent document 5) are known.
しかし、緑茶由来カテキン類は高価なので、虫歯菌、歯周病菌の増殖阻害有効量のカテキン類を食品に添加して安価に供給することは困難であった。またカテキン類は特有の不快な苦味を有し、ヒトの嗜好性を低下させるので、虫歯菌、歯周病菌の増殖阻害有効量のカテキン類を添加して嗜好性に優れる食品を供給するのは困難であった。 However, since catechins derived from green tea are expensive, it has been difficult to add catechins in an effective amount to inhibit the growth of caries and periodontal diseases and to supply them at low cost. Also, since catechins have a peculiar unpleasant bitter taste and reduce human preference, supplying foods with excellent palatability by adding an effective amount of catechins that inhibit the growth of caries and periodontal fungi It was difficult.
さらに、カテキン類は食品中のタンパク質との結合性が高いので、虫歯菌、歯周病菌の増殖阻害に対して有効量のカテキン類を添加したタンパク質性の食品を与えても、ヒトの口腔内にカテキン類を残留させ、抗菌活性を発揮させるのは困難であるという問題もあった。(例えば非特許文献6) Furthermore, since catechins have high binding properties to proteins in foods, even if protein foods containing an effective amount of catechins are added to inhibit the growth of caries and periodontal disease bacteria, Further, there is a problem that it is difficult to cause catechins to remain and exert antibacterial activity. (For example, Non-Patent Document 6)
一方、決明子抽出物、車前子抽出物、ハトムギエキス、キンマエキス等は満足な活性を持つものが得られていない。 On the other hand, those that have satisfactory activity have not been obtained, such as Seiko extract, car pea extract, pearl barley extract, betel extract and the like.
本発明は、上記事情を鑑みなされたもので、飲食品に対しても安心して使用できる安全性の高い子嚢菌類又は担子菌類由来の抽出物を有効成分とし、口腔用組成物及び飲食品などに配合または添加して使用される抗菌剤を安価に提供することを目的とする。 The present invention has been made in view of the above circumstances, and has a highly safe extract from Ascomycetes or Basidiomycetes that can be used with confidence for foods and drinks as an active ingredient, composition for oral cavity, food and drink, etc. It aims at providing the antibacterial agent mix | blended or added to and used at low cost.
本発明者らは、前記課題を解決するため、副作用がなく安全性が高く古来より利用されている子嚢菌類又は担子菌類に注目し、口腔疾患である虫歯(う蝕)の原因とされるストレプトコッカス・ミュータンス(S.mutans)、ストレプトコッカス・ソブリヌス(S.sobrinus)、歯周病の原因とされるアクチノマイセス・ビスコサス(A.viscosus)、ポルフィロモナス・ジンジバリス(P.gingivalis)、フゾバクテリウム・ヌクレイタム(F.nucleatum)、炎症性起因菌である溶血性連鎖球菌のストレプトコッカス・ピオゲネス(S.pyogenes)、食中毒の原因菌である黄色ブドウ球菌スタフィロコッカス・アウレウス(S.aureus)の増殖を抑制する素材を見出すため、抗菌試験を実施した。その結果、アオゾメタケ、アミガサタケ、アミヒカリタケ、アラゲカワキタケ、アラゲキクラゲ、イタチタケ、イヌセンボンタケ、ウシグソヒトヨタケ、ウスヒラタケ、ウチワタケ、エナラッシタケ、オオイチョウタケ、オオシロカラカサタケ、オオチリメンタケ、オオヒラタケ、オニフスベ、カイガラタケ、カミウロコタケ、カラカサタケ、カワキタケ、キクラゲ、キララタケ、クジラタケ、クリタケ、クロアワビタケ、ケガワタケ、コガネタケ、コフキサルノコシカケ、ゴムタケ、コムラサキシメジ、サガリハリタケ、サケツバタケ、サンコタケ、シハイタケ、シロオオハラタケ、シロナメツムタケ、シロモリノカサ、スギエダタケ、スギヒラタケ、スズメタケ、スッポンタケ、スルメタケ、センボンイチメガサ、ダイダイガサ、タマキクラゲ、タマチョレイタケ、タモギタケ、チャナメツムタケ、チャホウキタケ、ツエタケ、ツクリタケ、ツチスギタケ、ツチナメコ、トキイロヒラタケ、ナメコ、ニオウシメジ、ニクウスバタケ、ヌメリスギタケモドキ、ヌメリツバタケ、ヌメリツバタケモドキ、ネッタイカタハ、ネッタイカワキタケ、ネッタイヌメリタケ、ネンドタケ、ハナオチバタケ、ハナビラタケ、ハラタケ、ハリガネオチバタケ、ヒトクチタケ、ヒトヨタケ、ヒナノチャワンタケ、ヒメホウライタケ、ヒメマツタケ、ヒラタケ、ビロードツエタケ、ブクリョウ、ブナシメジ、ブナハリタケ、フミヅキタケ、ベッコウタケ、ホウネンタケ、ホシアンズタケ、マイタケ、マゴジャクシ、マスタケ、マツオウジ、ミドリスギタケ、ミヤマトンビマイタケ、ムキタケ、モエギタケ、モリハラタケ、ヤマブシタケ、レンガタケからなる群より選択される1種又は2種以上の子嚢菌類又は担子菌類より得られた抽出物が、抗菌活性を有することを見出し、本発明を完成させた。 In order to solve the above-mentioned problems, the present inventors pay attention to ascomycetes or basidiomycetes that have no side effects and are highly safe and have been used since ancient times, and are considered to be the cause of dental caries (caries) that are oral diseases. Streptococcus mutans (S.mutans), Streptococcus sobrinus (S.sobrinus), Actinomyces viscosus (P. gingivalis), P. gingivalis (fusobacterium) which is the cause of periodontal disease・ Proliferation of nucleatum (F. nucleatum), Streptococcus pyogenes (hemolytic streptococcus) which is an inflammatory causative bacterium, and Staphylococcus aureus (S. aureus) which is a causative bacterium of food poisoning Antibacterial tests were conducted to find materials to suppress. As a result, Aozometake, Amigasatake, Amhikaritake, Aragekawa kawatake, Arageki jellyfish, Itachitake, Inubonbontake, Ushigusu Toyotake, Ushiratake, Pricklytake, Enarashitake, Ootaketake, Oshitaketake, Takeshi Ootake , Kawataketake, jellyfish, Kiraratake, Whaletake, Kuritatake, Black-bellied Taketake, Bamboo shoot, Koganaketake, Kofukisarokoshitake, Gumtake, Komura-sakitake, Sagari Haritake, Salmonella, Mushroom Sulmethake, Senbon Ichimegasa, Daidaigasa, Tamaki Rage, tamachoreitake, tamamotake, chanametsumutake, chahou kitaketake, tsutaketake, tsukuritake, tsutsugitake, tsuchinameko, toukiirohiratake, namako, niyuushige, nikustaketake, numeritaketake, bamboo shoot , Nendotake, Hanauchitake, Hanataketake, Haritake, Hariganeotaketake, Hitokuchitake, Hitoyotake, Hinanochawantake, Himetakeraitake, Hirataketake, Hiratake, Velotus edulis, Bakurye, Bunataketake, Bamboo crispula , Mushroom, pine mushroom, green squirrel, Miyamatonbimaitake, Mukitake, Moegi Ke, Moriharatake, Hericium erinaceus, one or more of Ascomycetes or extract obtained from Basidiomycetes is selected from the group consisting of Rengatake is found to have antibacterial activity, and completed the present invention.
即ち、本発明は、上記の子嚢菌又は担子菌の抽出物を有効成分とする抗菌剤及びそれを用いた口腔用組成物並びに飲食品に関するものである。 That is, this invention relates to the antibacterial agent which uses the extract of said ascomycete or basidiomycetes as an active ingredient, the composition for oral cavity using the same, and food-drinks.
本発明の抗菌剤は、子嚢菌類及又は担子菌類由来の抽出物を有効成分とし、口腔疾患である虫歯(う蝕)の原因菌とされるストレプトコッカス・ミュータンス(Streptococcus mutans)、ストレプトコッカス・ソブリヌス(Streptococcus sobrinus)、歯周病の原因菌とされるとされるアクチノマイセス・ビスコサス(Actinomyces viscosus)、ポルフィロモナス・ジンジバリス(Porphyromonas gingivalis)、フゾバクテリウム・ヌクレイタム(Fusobacterium nucleatum)、炎症性起因菌である溶血性連鎖球菌のストレプトコッカス・ピオゲネス(Streptococcus pyogenes)、食中毒の原因菌である黄色ブドウ球菌スタフィロコッカス・アウレウス(Staphylococcus aureus)の増殖を抑制する効果を有する。 The antibacterial agent of the present invention comprises an extract derived from ascomycetes or basidiomycetes as an active ingredient, and Streptococcus mutans and Streptococcus sobrinus, which are causative bacteria for dental caries (caries) that are oral diseases. (Streptococcus sobrinus), Actinomyces viscosus, Porphyromonas gingivalis, Fusobacterium nucleatum, and inflammatory causative bacteria It has the effect of inhibiting the growth of Streptococcus pyogenes, a hemolytic streptococci, and Staphylococcus aureus, the causative fungus of Staphylococcus aureus.
発明品の原料となる子嚢菌類及び/又は担子菌類はナメコ、キクラゲ、ヤマブシタケ、ブクリョウはじめとして、いずれも生薬、食品として古くより用いられているものであり、これらの抽出物及びそれを配合した口腔用組成物並びに飲食品の安全性については全く問題がない。 Ascomycetes and / or basidiomycetes that are the raw materials of the invention products are names that have been used for a long time as herbal medicines, foods such as nameko, jellyfish, yamabushitake, bukuro, etc., and these extracts and blended with them There is no problem at all about the safety of oral compositions and foods and drinks.
本発明の抗菌剤は、自然界に豊富に存在する子嚢菌類及び担子菌類によるものであり、子実体のみでなく菌糸体の利用により安価に大量生産することが可能である。 The antibacterial agent of the present invention is derived from ascomycetous fungi and basidiomycetes that are abundant in nature, and can be mass-produced at low cost by using not only fruit bodies but also mycelium.
また、本発明の口腔用組成物及び飲食品は、緑茶抽出物等を配合した従来品と比べて本発明の抗菌剤の添加による風味の変化は認められず、よって、ヒトの嗜好性に優れている。 Further, the composition for oral cavity and food and drink of the present invention have no change in flavor due to the addition of the antibacterial agent of the present invention as compared with conventional products containing green tea extract and the like, and thus excellent in human palatability. ing.
子嚢菌又は担子菌は、生のまま、乾燥したものといずれの形態であっても本発明に利用できる。また、菌糸体、子実体(きのこ)どちらか一方、または両方を使用することができる。 Ascomycetes or basidiomycetes can be used in the present invention in any form, either raw or dried. In addition, either one or both of mycelia and fruit bodies (mushrooms) can be used.
上記子嚢菌及び担子菌原料から抽出物を得るためには、あらかじめ、適当な粉砕手段で粉砕すると良い。粉砕物から本発明の抽出物を得る方法については特に限定しないが、水、メタノール、エタノール並びにn−プロパノール等の低級アルコール、アセトン、酢酸エチル、ヘキサン、エーテル等の有機溶剤の1種または2種以上の混合溶媒を加え、従来行われている抽出方法によって、本発明の子嚢菌及び担子菌抽出物を得ることができる。しかし、本発明はヒトに、または食物として用いるものであることを考慮すると、抽出溶剤としては安全性の面から水とエタノールとの組み合わせを用いるのが好ましい。 In order to obtain an extract from the ascomycete and basidiomycete raw material, it is preferable to pulverize in advance by an appropriate pulverization means. The method for obtaining the extract of the present invention from the pulverized product is not particularly limited, but one or two kinds of organic solvents such as water, methanol, ethanol and lower alcohols such as n-propanol, acetone, ethyl acetate, hexane and ether. The above-mentioned mixed solvent is added, and the ascomycete and basidiomycete extract of the present invention can be obtained by the conventional extraction method. However, considering that the present invention is used for humans or as food, it is preferable to use a combination of water and ethanol as an extraction solvent from the viewpoint of safety.
抽出条件としては高温、室温、低温のいずれかの温度で抽出することができるが、50〜90℃で1〜5時間程度または室温で24時間程度が好ましい。抽出液は濾過し、抽出溶剤を留去したあと、減圧下において濃縮または凍結乾燥したものを使用することができる。また、これらの抽出物を有機溶剤、カラムクロマトグラフィ等により分画精製したものも使用することができる。 As extraction conditions, extraction can be carried out at any one of high temperature, room temperature, and low temperature, but preferably 50 to 90 ° C. for about 1 to 5 hours or room temperature for about 24 hours. The extract can be filtered and the extract solvent can be distilled off, followed by concentration or lyophilization under reduced pressure. In addition, those obtained by fractionating and purifying these extracts using an organic solvent, column chromatography, or the like can also be used.
また、本発明の抗菌剤を、練り歯磨き、粉歯磨き、液状歯磨、洗口剤、義歯洗浄剤、うがい薬、歯肉マッサージクリームなどの口腔用組成物に配合してもよい。 Moreover, you may mix | blend the antibacterial agent of this invention with oral compositions, such as toothpaste, toothpaste, liquid toothpaste, a mouthwash, a denture cleaning agent, a mouthwash, and a gum massage cream.
また本発明の抗菌剤は、安全性が高いことから、食品素材として飲食品に用いる場合、菓子類(ガム、キャンディ、キャラメル、チョコレート、クッキー、スナック、ゼリー、グミ、錠菓等)、麺類(そば、うどん、ラーメン等)、乳製品(ミルク、アイスクリーム、ヨーグルト等)、調味料(醤油、味噌等)、スープ類、飲料(ジュース、コーヒー、紅茶、茶、炭酸飲料、スポーツ飲料等)をはじめとする一般食品や、健康食品(錠剤、カプセル等)、栄養補助食品(栄養ドリンク等)に配合することができる。また、インスタント食品に添加してもよい。 In addition, since the antibacterial agent of the present invention is highly safe, when used for food and drink as a food material, confectionery (gum, candy, caramel, chocolate, cookie, snack, jelly, gummy, tablet confection etc.), noodles ( Soba, udon, ramen etc.), dairy products (milk, ice cream, yogurt, etc.), seasonings (soy sauce, miso etc.), soups, beverages (juice, coffee, tea, tea, carbonated drinks, sports drinks, etc.) It can be blended in general foods such as health foods (tablets, capsules, etc.) and dietary supplements (nutrient drinks, etc.). Moreover, you may add to an instant food.
上記のような日常使用する口腔用組成物や日常的に摂取する飲食品に、本発明による安全性の高い抗菌剤を配合することで、抗菌剤を日常的に摂取することが可能となり、虫歯、歯周病等の予防が容易且つ気軽に実行可能となる。また、口腔用組成物や飲食品に抗菌剤を配合することで、抗菌剤の口中での滞在時間が長くなり、抗菌剤が口腔中に広く行き渡る等の更なる効果が付加されるため特に好ましい。具体的には、ガムやキャラメルやグミやキャンディや練り歯磨きや粉歯磨きや歯肉マッサージクリームに抗菌剤を配合することで抗菌剤の口中での滞在時間が長くなり非常に好ましい。また更に飲料や液状歯磨や洗口剤やうがい薬に抗菌剤を配合することで、抗菌剤が口腔中全体(歯の隙間等)に隈なく行き渡るため非常に好ましい。 By incorporating the highly safe antibacterial agent according to the present invention into the daily oral composition as described above and daily ingested foods and drinks, it becomes possible to ingest the antibacterial agent on a daily basis. In addition, prevention of periodontal disease and the like can be easily and easily performed. In addition, it is particularly preferable to add an antibacterial agent to the oral composition or food / drink because the antibacterial agent stays in the mouth for a long time and the antibacterial agent is further spread throughout the mouth. . Specifically, the antibacterial agent stays in the mouth for a long time by adding an antibacterial agent to gum, caramel, gummy, candy, toothpaste, powder toothpaste and gum massage cream, which is very preferable. Furthermore, by adding an antibacterial agent to beverages, liquid dentifrices, mouthwashes, and mouthwashes, the antibacterial agent spreads throughout the mouth (such as teeth gaps), which is very preferable.
本発明の口腔用組成物における上記抗菌剤の配合量は、使用形態あるいは使用目的によって適宜選定することができるが、対象となる細菌の生育を阻止又は抑制できる量の抗菌剤を含むことが必要である。基本的には、後述する細菌に対する最小阻止濃度(MIC)を基準にして、最小阻止濃度の1〜10000倍程度の濃度になるよう配合することが望ましく、より具体的には、通常、組成物全体の質量に対して0.001〜5%(質量%、以下同様)、好ましくは0.01%〜5%、より好ましくは0.05%〜2%程度の配合量が望ましい。 The blending amount of the antibacterial agent in the oral composition of the present invention can be appropriately selected depending on the use form or purpose of use, but it is necessary to include an amount of the antibacterial agent that can prevent or suppress the growth of the target bacteria. It is. Basically, it is desirable to formulate the composition to a concentration of about 1 to 10,000 times the minimum inhibitory concentration based on the minimum inhibitory concentration (MIC) against bacteria described below. A blending amount of about 0.001 to 5% (mass%, the same applies hereinafter), preferably 0.01% to 5%, more preferably about 0.05% to 2% is desirable with respect to the total mass.
本発明品の原料となる子嚢菌類及び担子菌類はアミガサタケ、ナメコ、ヤマブシタケ、ブクリョウをはじめとして、いずれも生薬、食品として古くより用いられているものであり、これらの抽出物及びこれを配合した口腔用組成物並びに飲食品の安全性については全く問題ない。 Ascomycetes and basidiomycetes that are the raw materials of the present invention products have been used for a long time as herbal medicines, foods, including morel mushrooms, sea cucumbers, yamabushitake mushrooms, and bucuryos. There is no problem with the safety of the oral composition and food and drink.
以下、試験例を挙げて本発明品を更に詳細に説明するが、それらによって本発明品の範囲を制限するものではない。 Hereinafter, although a test example is given and this invention product is demonstrated still in detail, the range of this invention product is not restrict | limited by them.
本試験は本発明の子嚢菌類及び担子菌類の抽出物の虫歯(う蝕)の原因とされる菌、歯周病に関与するとされる菌、溶血性連鎖球菌、病原性ブドウ球菌に対する増殖抑制効果を調べるために、次に示す試験方法(供試試料、供試菌株、使用培地、試験法)により実施した。 This test is to suppress the growth of the extracts of the ascomycetes and basidiomycetes of the present invention against the caries that cause caries (caries), the bacteria that are related to periodontal disease, hemolytic streptococci, and pathogenic staphylococci In order to investigate the effect, the following test methods (test sample, test strain, medium used, test method) were performed.
1)供試試料
以下の方法で作製した子嚢菌又は担子菌抽出物を単独で、またウスヒラタケ及びハナビラタケ菌糸体50%エタノール抽出物を混合して使用した。
1) Test sample Ascomycetes or basidiomycete extracts prepared by the following method were used alone, and a mixture of Usuhiratake and Hanabiratake mycelium 50% ethanol extract was used.
ヤマブシタケ子実体の凍結乾燥粉末30gに50%エタノール600mlを加え、還流冷却器をつけて、90℃で1時間還流しながら抽出した。得られた抽出液をろ別し、溶媒を除去した後、凍結乾燥することにより抽出物を12.0g得た。 To 30 g of freeze-dried powder of Yamabushitake fruit body, 600 ml of 50% ethanol was added, and a reflux condenser was attached, followed by extraction while refluxing at 90 ° C. for 1 hour. The obtained extract was filtered, the solvent was removed, and the residue was freeze-dried to obtain 12.0 g of the extract.
同様にして、キクラゲ、ブナシメジ及び対照例として緑茶について、50%エタノールを用いて抽出し、抽出液を濃縮または凍結乾燥することにより抽出物を調製した。抽出物の収率を表1に示した。 Similarly, extract was prepared by extracting 50% ethanol with fungus, beech shimeji mushroom, and green tea as a control example, and concentrating or lyophilizing the extract. The yield of the extract is shown in Table 1.
キクラゲ菌糸体の凍結乾燥燥粉末1gに水50mlを加え、室温で24時間振とうしながら抽出した。得られた抽出液をろ別し、溶媒を除去した後、凍結乾燥することにより抽出物を0.12g得た。 50 g of water was added to 1 g of freeze-dried powder of fungus mycelium and extracted with shaking at room temperature for 24 hours. The obtained extract was filtered off, the solvent was removed, and the residue was freeze-dried to obtain 0.12 g of the extract.
同様にして子嚢菌及び担子菌菌糸体93種の凍結乾燥粉末について、水を用いて抽出し、抽出液を濃縮または凍結乾燥することにより抽出物を調製した。抽出物の収率を表1に示した。 Similarly, lyophilized powders of 93 species of ascomycetes and basidiomycetous mycelium were extracted using water, and the extract was concentrated or freeze-dried to prepare an extract. The yield of the extract is shown in Table 1.
キクラゲ菌糸体の凍結乾燥燥粉末1gに50%エタノール50mlを加え、室温で24時間振とうしながら抽出した。得られた抽出液をろ別し、溶媒を除去した後、凍結乾燥することによりそれぞれ抽出物を0.12g得た。 50 g of ethanol was added to 1 g of freeze-dried powder of fungus mycelium and extracted with shaking at room temperature for 24 hours. The obtained extract was filtered, the solvent was removed, and freeze-dried to obtain 0.12 g of the extract.
同様にして子嚢菌及び担子菌菌糸体93種の凍結乾燥粉末について、50%エタノールを用いて抽出し、抽出液を濃縮または凍結乾燥することにより抽出物を調製した。抽出物の収率を表1に示した。 Similarly, freeze-dried powders of 93 species of ascomycetes and basidiomycetous mycelium were extracted using 50% ethanol, and the extract was concentrated or freeze-dried to prepare an extract. The yield of the extract is shown in Table 1.
ヤマブシタケ菌糸体の凍結乾燥粉末1gに100%アセトン50mlを加え、還流冷却器をつけて、1時間還流しながら抽出した。得られた抽出物をろ別し、溶媒を除去した後、凍結乾燥することにより抽出物を0.29g得た。 50 ml of 100% acetone was added to 1 g of freeze-dried powder of Yamabushitake mycelium, and the mixture was extracted with refluxing for 1 hour with a reflux condenser. The obtained extract was filtered and the solvent was removed, followed by lyophilization to obtain 0.29 g of the extract.
同様にしてウスヒラタケについて100%アセトンを用いて抽出し、抽出液を濃縮または凍結乾燥することにより抽出物を調製した。各抽出物の収率を表2に示した。 Similarly, Ushiratake was extracted with 100% acetone, and the extract was prepared by concentrating or lyophilizing the extract. The yield of each extract is shown in Table 2.
ヤマブシタケ菌糸体の凍結乾燥粉末1gに100%ヘキサン50mlを加え、還流冷却器をつけて、1時間還流しながら抽出する。得られた抽出物をろ別し、溶媒を除去した後、凍結乾燥することにより抽出物を0.05g得た。 Add 50 ml of 100% hexane to 1 g of Yamabushitake mycelium lyophilized powder, attach a reflux condenser and extract with reflux for 1 hour. The obtained extract was filtered off, the solvent was removed, and freeze-dried to obtain 0.05 g of the extract.
同様にしてウスヒラタケについて100%ヘキサンを用いて抽出し、抽出液を濃縮または凍結乾燥することにより抽出物を調製した。各抽出物の収率を表2に示した。 Similarly, Ushiratake was extracted with 100% hexane, and the extract was concentrated or freeze-dried to prepare an extract. The yield of each extract is shown in Table 2.
2)供試菌株
虫歯の原因とされる菌としてストレプトコッカス・ミュータンス(S.mutans)、ストレプトコッカス・ソブリナス(S.sobrinus)。歯周病に関与する菌としてアクチノマイセス・ビスコーサス(A.viscosus)、ポルフィロモナス・ジンジバリス(P.gingivalis)、フゾバクテリウム・ヌクレイタム(F.nucleatum)。溶血性連鎖球菌(ストレプトコッカス・ピオゲネス(S.pyogenes))。黄色ブドウ球菌(スタフィロコッカス・アウレウス(S.aureus))。
2) Test strains Streptococcus mutans (S.mutans) and Streptococcus sobrinus (S.sobrinus) are the causative agents of caries. Actinomyces biscosus (A. viscosus), Porphyromonas gingivalis (P. gingivalis), Fusobacterium nucleatum (F. nucleatum) as bacteria involved in periodontal disease. Hemolytic streptococci (Streptococcus pyogenes). Staphylococcus aureus (S. aureus).
3)使用培地および前培養条件
上記したストレプトコッカス・ミュータンス(S.mutans)、ストレプトコッカス・ソブリナス(S.sobrinus)およびストレプトコッカス・ピオゲネス(S.pyogenes)はブレインハートインヒュージョン(BHI)液体培地に摂取し、37℃で24時間培養し前培養液とした。アクチノマイセス・ビスコーサス(A.viscosus)、ポルフィロモナス・ジンジバリス(P.gingivalis)、フゾバクテリウム・ヌクレイタム(F.nucleatum)はイーストエキストラクト(0.3g)、トリプチケースソイブロス(3g)、ヘミン(0.5mg)、メナジオン(0.05mg)を水へ添加し100mlに調製した液体培地に摂取し、37℃で24〜48時間嫌気的に培養し前培養液とした。スタフィロコッカス・アウレウス(S.aureus)はニュートリエントブロス(0.8g)、イーストエキストラクト(0.5g)、グルコース(0.1g)を混合し調製した液体培地に摂取し、37℃で24時間培養し前培養液とした。
3) Use medium and pre-culture conditions The above-mentioned Streptococcus mutans, S. sobrinus and S. pyogenes are ingested in a brain heart infusion (BHI) liquid medium. Incubated at 37 ° C. for 24 hours to obtain a preculture solution. Actinomyces viscosus, Porphyromonas gingivalis (P.gingivalis), Fusobacterium nucleatum (F.nucleatum) are yeast extract (0.3g), trypticase soy broth (3g), hemin (0.5 mg) and menadione (0.05 mg) were added to water and taken in a liquid medium prepared to 100 ml, and anaerobically cultured at 37 ° C. for 24-48 hours to obtain a preculture solution. Staphylococcus aureus (S. aureus) is ingested in a liquid medium prepared by mixing nutritive broth (0.8 g), yeast extract (0.5 g), and glucose (0.1 g). The culture was performed for a period of time to prepare a preculture solution.
4)試験法
上記供試試料1.6mgを2%エタノール溶液1mlに溶解し子嚢菌および担子菌抽出液として96穴マイクロプレート上に2連で100μl添加した。なお2種類の供試試料を用いる時は各0.8mg(合計1.6mg)を2%エタノール溶液1mlに溶解し96穴マイクロプレート上に2連で100μl添加した。2%エタノール溶液を用いて順次希釈することにより、96穴マイクロプレートに2倍希釈系列を作成した。調製した各ウェルに2倍濃度培地で希釈した各菌体を100μ添加し37℃で24〜48時間、虫歯の原因菌とされるストレプトコッカス・ミュータンス(S.mutans)、ストレプトコッカス・ソブリナス(S.sobrinusr)、溶血性連鎖球菌(ストレプトコッカス・ピオゲネス(S.pyogenes))、黄色ブドウ球菌(スタフィロコッカス・アウレウス(S.aureus)は好気条件で、歯周病に関与する菌アクチノマイセス・ビスコーサス(A.viscosus)、ポルフィロモナス・ジンジバリス(P.gingivalis)、フゾバクテリウム・ヌクレイタム(F.nucleatum)は嫌気条件で静地培養した。子嚢菌および担子菌抽出物最終濃度は800μg/ml、400μg/ml、200μg/ml、100μg/ml、50μg/ml、25μg/ml、12.5μg/ml、6.25μg/ml、3.13μg/ml、1.56μg/ml、0.78μg/mlとした。各ウェルの濁度から最小発育阻止濃度(以下、MICと略称する)を測定した。
(3)試験結果
子実体の50%エタノール抽出物を用いた結果を表3に、菌糸体の水抽出物を用いた結果を表4に、菌糸体の50%エタノール抽出物を用いた結果を表5に、菌糸体の100%アセトン抽出物を用いた結果を表6に、菌糸体の100%へキサン抽出物を用いた結果を表7に、2種類の菌糸体の50%エタノール抽出物を混合して用いた結果を表8に示した。
4) Test method 1.6 mg of the above test sample was dissolved in 1 ml of 2% ethanol solution, and 100 μl was added in duplicate to a 96-well microplate as an extract of ascomycetes and basidiomycetes. When two kinds of test samples were used, 0.8 mg (1.6 mg in total) was dissolved in 1 ml of 2% ethanol solution, and 100 μl was added in duplicate to a 96-well microplate. A 2-fold dilution series was prepared in a 96-well microplate by sequentially diluting with a 2% ethanol solution. 100 μl of each bacterial cell diluted with a double-concentration medium was added to each prepared well, and Streptococcus mutans and Streptococcus sobrinus (S. sobrinusr), hemolytic streptococci (Streptococcus pyogenes), Staphylococcus aureus (S. aureus) are aerobic conditions and are responsible for periodontal disease Actinomyces biscorus (A. viscosus), P. gingivalis, and F. nucleatum were statically cultured under anaerobic conditions, and the final concentrations of ascomycetes and basidiomycetous extracts were 800 μg / ml and 400 μg / ml. ml, 200 μg / ml, 100 μg / ml, 50 μg / ml, 25 μg / ml, 12.5 μg / ml, 6.25 μg / ml, 3.13 μg / ml, 1.56 μg / ml, and 0.78 μg / ml The minimum inhibitory concentration (hereinafter abbreviated as MIC) was measured from the turbidity of each well.
(3) Test results The results of using 50% ethanol extract of fruit bodies are shown in Table 3, the results of using mycelium water extract are shown in Table 4, and the results of using 50% ethanol extract of mycelium are shown. Table 5 shows the results of using 100% acetone extract of mycelium, Table 6 shows the results of using 100% hexane extract of mycelium, and Table 7 shows 50% ethanol extract of two types of mycelium. Table 8 shows the result of mixing and using.
(4)評価結果
1.担子菌及び子嚢菌の溶媒抽出物は口腔内う蝕に関与するとされている細菌又は/及び歯周病に関与するとされている細菌又は/及び黄色ブドウ球菌又は/及び溶血性連鎖球菌に対して抗菌性をを示す事が明らかとなった。
(4) Evaluation results Solvent extracts of basidiomycetes and ascomycetes against bacteria that are supposed to be involved in oral cavity and / or bacteria that are supposed to be involved in periodontal disease and / or Staphylococcus aureus and / or hemolytic streptococci It became clear that it showed antibacterial properties.
2.溶媒の種類については、低極性溶媒(例えば50%エタノール、アセトン、ヘキサン)を用いて抽出したサンプルの方が抗菌性に優れていることが明らかとなった。 2. As for the type of the solvent, it was revealed that the sample extracted with a low polarity solvent (for example, 50% ethanol, acetone, hexane) is superior in antibacterial properties.
3.2種類以上の菌糸体抽出物を混合して用いることにより1種類だけで用いた時より抗菌活性の対象となる細菌数の増加が認められ、混合使用の効果が確かめられた。 3. By using two or more types of mycelium extracts mixed and used, an increase in the number of bacteria targeted for antibacterial activity was observed compared with the use of only one type, and the effect of the mixed use was confirmed.
4.抗菌性が認められている緑茶抽出物及び市販品緑茶抽出物と比較して担子菌、及び子嚢菌抽出物は抗菌活性に優れていることが認められた。 4). The basidiomycetes and ascomycete extracts were found to be superior in antibacterial activity as compared to the green tea extract and the commercially available green tea extract that are recognized as having antibacterial properties.
以上の試験結果により、本発明品である上記担子菌及び子嚢菌より得られた抽出物は、口腔疾患である虫歯(う蝕)の原因とされるストレプトコッカス・ミュータンス(S.mutans)、ストレプトコッカス・ソブリヌス(S.sobrinus)、歯周病の原因とされるとされるアクチノマイセス・ビスコサス(A.viscosus)、ポルフィロモナス・ジンジバリス(P.gingivalis)、フゾバクテリウム・ヌクレイタム(F.nucleatum)、炎症性起因菌である溶血性連鎖球菌のストレプトコッカス・ピオゲネス(S.pyogenes)、食中毒の原因菌である黄色ブドウ球菌スタフィロコッカス・アウレウス(S.aureus)の増殖抑制活性を持つことが今回初めて明らかとなった。 Based on the above test results, the extract obtained from the above basidiomycetes and ascomycetes according to the present invention was obtained from Streptococcus mutans and Streptococcus, which are the cause of dental caries.・ S. sobrinus, Actinomyces viscosus (P. gingivalis), Fusobacterium nucleatum (F. nucleatum), It is the first time to show the growth-inhibitory activity of Streptococcus pyogenes (Streptococcus pyogenes), an inflammatory pathogen, and Staphylococcus aureus (S. aureus), the causative agent of food poisoning It became.
以下、実施例を挙げて本発明品を更に詳細に説明するが、それらによって本発明品の範囲を制限するものではない。 EXAMPLES Hereinafter, although an Example is given and this invention product is demonstrated further in detail, the range of this invention product is not restrict | limited by them.
ヤマブシタケ子実体50%エタノール抽出物を用い、以下の処方にて、錠剤を調製した。 Using a 50% ethanol extract of Yamabushitake fruiting body, a tablet was prepared according to the following formulation.
D−マンニトール 44.0部
乳糖 40.0部
結晶セルロース 10.0部
ヒドロキシプロピルセルロース 5.0部
ヤマブシタケ子実体50%エタノール抽出物 1.0部
100.0
D-mannitol 44.0 parts Lactose 40.0 parts Crystalline cellulose 10.0 parts Hydroxypropyl cellulose 5.0 parts Yamabushitake fruit body 50% ethanol extract 1.0 part
100.0
ヤマブシタケ菌糸体100%アセトン抽出物を用い、以下の処方にて、トローチ剤を調製した。 Using a 100% acetone extract of Yamabushitake mycelium, a lozenge was prepared according to the following formulation.
ブドウ糖 72.3部
乳糖 19.0部
アラビアゴム 6.0部
香料 1.0部
モノフルオロリン酸ナトリウム 0.7部
ヤマブシタケ菌糸体100%アセトン抽出物 1.0部
100.0
Glucose 72.3 parts Lactose 19.0 parts Gum arabic 6.0 parts Fragrance 1.0 parts Sodium monofluorophosphate 0.7 parts Yamabushitake mycelium 100% acetone extract 1.0 parts
100.0
ヤマブシタケ菌糸体100%ヘキサン抽出物を用い、以下の処方にて、含嗽剤を調製した。 Using a 100% hexane extract of Yamabushitake mycelium, a gargle was prepared according to the following formulation.
エタノール 2.0 部
香料 1.0 部
サッカリン 0.05部
塩酸クロルヘキシジン 0.01部
ヤマブシタケ菌糸体100%ヘキサン抽出物 0.5 部
水 96.44部
100.0
Ethanol 2.0 parts Fragrance 1.0 parts Saccharin 0.05 parts Chlorhexidine hydrochloride 0.01 parts Yamabushitake mycelium 100% hexane extract 0.5 parts Water 96.44 parts
100.0
ヤマブシタケ菌糸体50%エタノール抽出物を用い、以下の処方にて、練り歯磨を調製した。 A toothpaste was prepared using an extract of Yamabushitake mycelium 50% ethanol according to the following formulation.
炭酸カルシウム 50.0 部
グリセリン 20.0 部
カルボオキシメチルセルロース 2.0 部
ラウリル硫酸ナトリウム 2.0 部
香料 1.0 部
サッカリン 0.1 部
ヤマブシタケ菌糸体50%エタノール抽出物 1.0 部
クロルヘキシジン 0.01部
水 23.9 部
100.0
Calcium carbonate 50.0 parts Glycerin 20.0 parts Carboxymethyl cellulose 2.0 parts Sodium lauryl sulfate 2.0 parts Fragrance 1.0 part Saccharin 0.1 part Yamabushitake mycelium 50% ethanol extract 1.0 part Chlorhexidine 0. 01 parts water 23.9 parts
100.0
ヤマブシタケ菌糸体水抽出物を用い、以下の処方にて、チューインガムを調製した。 A chewing gum was prepared by using the Yamabushitake mycelium water extract according to the following formulation.
ガムベース 20.0部
砂糖 55.0部
グルコース 15.0部
水飴 9.0部
香料 0.5部
ヤマブシタケ菌糸体水抽出物 0.5部
100.0
Gum base 20.0 parts Sugar 55.0 parts Glucose 15.0 parts Minamata 9.0 parts Fragrance 0.5 parts Yamabushitake mycelium water extract 0.5 parts
100.0
アミガサタケ菌糸体水抽出物を用い、以下の処方にて、キャンディを調製した。 Candy was prepared with the following prescription using agaricus mycelium water extract.
砂糖 50.0部
水飴 34.0部
香料 0.5部
アミガサタケ菌糸体水抽出物 0.5部
水 15.0部
100.0
Sugar 50.0 parts Minamata 34.0 parts Fragrance 0.5 parts Amigasatake mycelium water extract 0.5 parts Water 15.0 parts
100.0
キクラゲ菌糸体50%エタノール抽出物抽出物を用い、以下の処方にて、錠菓を調製した。 Tablet confectionery was prepared according to the following prescription using a 50% ethanol extract of fungus mycelium.
砂糖 76.4部
グルコース 19.0部
ショ糖脂肪酸エステル 0.2部
香料 0.2部
キクラゲ菌糸体50%エタノール抽出物 0.1部
水 4.1部
100.0
Sugar 76.4 parts Glucose 19.0 parts Sucrose fatty acid ester 0.2 parts Fragrance 0.2 parts Mulberry mycelium 50% ethanol extract 0.1 parts Water 4.1 parts
100.0
ブナシメジ菌糸体水抽出物を用い、以下の処方にて、グミゼリーを調製した。 Gummy jelly was prepared with the following prescription using Buna shimeji mycelium water extract.
ゼラチン 60.0 部
水飴 23.0 部
砂糖 8.5 部
植物油脂 4.5 部
マンニトール 2.95部
レモン果汁 1.0 部
ブナシメジ菌糸体水抽出物 0.05部
100.0
Gelatin 60.0 parts Waterpox 23.0 parts Sugar 8.5 parts Vegetable oil 4.5 parts Mannitol 2.95 parts Lemon juice 1.0 part Bunashimeji mycelium water extract 0.05 parts
100.0
ナメコ菌糸体50%エタノール抽出物を用い、以下の処方にて、チョコレートを調製した。 Chocolate was prepared according to the following prescription using a nameko mycelium 50% ethanol extract.
粉糖 40.8部
カカオビター 20.0部
全脂粉乳 20.0部
カカオバター 17.0部
マンニトール 1.0部
ナメコ菌糸体50%エタノール抽出物 1.0部
香料 0.2部
100.0
Powdered sugar 40.8 parts Cocoa bitter 20.0 parts Whole milk powder 20.0 parts Cocoa butter 17.0 parts Mannitol 1.0 parts Nameko mycelium 50% ethanol extract 1.0 parts Fragrance 0.2 parts
100.0
アミガサタケ菌糸体50%エタノール抽出物を用い、以下の処方にて、ビスケットを調製した。 Biscuits were prepared according to the following formulation using a 50% ethanol extract of agaric mycelium.
薄力1級 25.59部
中力1級 22.22部
精白糖 4.8 部
食塩 0.73部
ブドウ糖 0.78部
パームショートニング 11.78部
炭酸水素ナトリウム 0.17部
重亜硫酸ナトリウム 0.16部
米分 1.45部
全脂粉乳 1.16部
代用粉乳 0.29部
アミガサタケ菌糸体50%エタノール抽出物 0.5 部
水 残
100.0
Low strength grade 25.59 parts Medium strength grade 22.22 parts White sugar 4.8 parts Salt 0.73 parts Glucose 0.78 parts Palm shortening 11.78 parts Sodium bicarbonate 0.17 parts Sodium bisulfite 0. 16 parts Rice 1.45 parts Whole milk powder 1.16 parts Substitute milk powder 0.29 parts Amigasatake mycelium 50% ethanol extract 0.5 parts Water residue
100.0
ヤマブシタケ菌糸体水抽出物を用い、以下の処方にて、アイスクリームを調製した。 An ice cream was prepared using the Yamabushitake mycelium water extract according to the following formulation.
脱脂粉乳 50.0部
生クリーム 25.0部
砂糖 10.0部
卵黄 10.0部
ヤマブシタケ菌糸体水抽出物 1.0部
香料 0.1部
水 残
100.0
Nonfat dry milk 50.0 parts Fresh cream 25.0 parts Sugar 10.0 parts Egg yolk 10.0 parts Yamabushitake mycelium water extract 1.0 part Fragrance 0.1 part Water residue
100.0
ブクリョウ菌糸体水抽出物を用い、以下の処方にて、シャーベットを調製した。 A sherbet was prepared with the following prescription using an aqueous extract of mycomycetes.
オレンジ果汁 25.0部
砂糖 25.0部
卵白 10.0部
ブクリョウ菌糸体水抽出物 2.0部
水 38.0部
100.0
Orange juice 25.0 parts Sugar 25.0 parts Egg white 10.0 parts Bukuryo mycelium water extract 2.0 parts Water 38.0 parts
100.0
ブナシメジ子実体水抽出物を用い、以下の処方にて、飲料を調製した。 Using Buna shimeji fruit body water extract, a beverage was prepared according to the following formulation.
オレンジ果汁 30.0 部
異性化糖 15.24部
クエン酸 0.1 部
ビタミンC 0.04部
香料 0.1 部
ブナシメジ子実体水抽出物 1.0 部
水 残
100.0
Orange juice 30.0 parts Isomerized sugar 15.24 parts Citric acid 0.1 parts Vitamin C 0.04 parts Fragrance 0.1 parts Bunashimaji fruit body water extract 1.0 parts Water residue
100.0
アミガサタケ菌糸体水抽出物を用い、以下の処方にて、スープを調製した。 A soup was prepared with the following prescription using an extract of mycelia mushroom mycelium.
牛乳 60.00部
たまねぎ 20.00部
にんじん 10.00部
野菜ブイヨン 1.00部
バター 0.10部
コショウ 0.05部
塩 0.05部
アミガサタケ菌糸体水抽出物 1.0 部
水 残
100.0
Milk 60.00 parts Onion 20.00 parts Carrot 10.00 parts Vegetable bouillon 1.00 parts Butter 0.10 parts Pepper 0.05 parts Salt 0.05 parts Amigasatake mycelium water extract 1.0 parts Water residue
100.0
ウスヒラタケ菌糸体水抽出物とハナビラタケ菌糸体水抽出物の混合物を用い、以下の処方にて、ジャムを調製した。 A jam was prepared using a mixture of Usuhiratake mycelium water extract and Hanabiratake mycelium water extract with the following formulation.
果肉 4.0部
砂糖 65.0部
清澄果汁 25.0部
クエン酸 0.5部
ウスヒラタケ菌糸体水抽出物と
ハナビラタケ菌糸体水抽出物の混合物 2.0部
水 残
100.0
Pulp 4.0 parts Sugar 65.0 parts Clarified fruit juice 25.0 parts Citric acid 0.5 parts Mix of Usuhiratake mycelium water extract and Hanabiratake mycelium water extract 2.0 parts Water residue
100.0
尚、何れの実施例にて得られた本発明の口腔用組成物及び飲食品も本発明の抗菌剤の添加による風味の変化は認められず、その結果、緑茶抽出物等を配合した従来品と比べて、本発明によれば、ヒトの嗜好性に優れた製品の供給が可能となった。 In addition, neither the oral composition of this invention obtained in any Example and the food-drinks showed the change of the flavor by addition of the antibacterial agent of this invention, As a result, the conventional product which mix | blended green tea extract etc. As compared with the above, according to the present invention, it has become possible to supply a product having excellent human taste.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011211692A JP5480864B2 (en) | 2011-09-27 | 2011-09-27 | Antibacterial agent and oral composition containing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011211692A JP5480864B2 (en) | 2011-09-27 | 2011-09-27 | Antibacterial agent and oral composition containing the same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005187494A Division JP5017697B2 (en) | 2005-06-27 | 2005-06-27 | Antibacterial agent |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013169750A Division JP5744985B2 (en) | 2013-08-19 | 2013-08-19 | Antibacterial agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012051897A true JP2012051897A (en) | 2012-03-15 |
JP5480864B2 JP5480864B2 (en) | 2014-04-23 |
Family
ID=45905650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011211692A Expired - Fee Related JP5480864B2 (en) | 2011-09-27 | 2011-09-27 | Antibacterial agent and oral composition containing the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5480864B2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014148501A (en) * | 2013-01-10 | 2014-08-21 | Yakkosoen Kenkyusho Co Ltd | Ameliorating or improving agent for oral function, and drugs, quasi drugs, cosmetics or foods and drinks containing thereof |
CN104561137A (en) * | 2015-01-15 | 2015-04-29 | 合肥工业大学 | Method for producing polyphenol by fermenting lachnum |
JP2015113300A (en) * | 2013-12-11 | 2015-06-22 | 日本メナード化粧品株式会社 | Immunostimulator |
JP2016044153A (en) * | 2014-08-25 | 2016-04-04 | 国立大学法人鳥取大学 | Antimicrobial agent containing volatile substance produced by hypsizigus marmoreus cultured cell |
KR101793910B1 (en) | 2015-03-04 | 2017-11-07 | 대한민국 | composition for natural nematicidal and nematocide comprising the same |
CN109820778A (en) * | 2019-02-20 | 2019-05-31 | 田朝晖 | A kind of hickory chick biofermentation bacterium solution composite skin care product and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000247900A (en) * | 1999-03-01 | 2000-09-12 | Agency Of Ind Science & Technol | Antibacterial agent |
JP2001206830A (en) * | 2000-01-26 | 2001-07-31 | Lion Corp | Composition for oral cavity |
JP2004051603A (en) * | 2002-07-24 | 2004-02-19 | Asahi Denka Kogyo Kk | Agent for oral cavity |
JP2005097127A (en) * | 2003-09-22 | 2005-04-14 | Unitika Ltd | Antimicrobial agent |
-
2011
- 2011-09-27 JP JP2011211692A patent/JP5480864B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000247900A (en) * | 1999-03-01 | 2000-09-12 | Agency Of Ind Science & Technol | Antibacterial agent |
JP2001206830A (en) * | 2000-01-26 | 2001-07-31 | Lion Corp | Composition for oral cavity |
JP2004051603A (en) * | 2002-07-24 | 2004-02-19 | Asahi Denka Kogyo Kk | Agent for oral cavity |
JP2005097127A (en) * | 2003-09-22 | 2005-04-14 | Unitika Ltd | Antimicrobial agent |
Non-Patent Citations (2)
Title |
---|
JPN6011039554; 茨城大学農学部学術報告,第28号, p.1-9,1980年 * |
JPN6011039560; メルクマニュアル 第16版,1995年5月1日 第3刷, p.2373-2375, (有)メディカルブックサービス * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014148501A (en) * | 2013-01-10 | 2014-08-21 | Yakkosoen Kenkyusho Co Ltd | Ameliorating or improving agent for oral function, and drugs, quasi drugs, cosmetics or foods and drinks containing thereof |
JP2015113300A (en) * | 2013-12-11 | 2015-06-22 | 日本メナード化粧品株式会社 | Immunostimulator |
JP2016044153A (en) * | 2014-08-25 | 2016-04-04 | 国立大学法人鳥取大学 | Antimicrobial agent containing volatile substance produced by hypsizigus marmoreus cultured cell |
CN104561137A (en) * | 2015-01-15 | 2015-04-29 | 合肥工业大学 | Method for producing polyphenol by fermenting lachnum |
KR101793910B1 (en) | 2015-03-04 | 2017-11-07 | 대한민국 | composition for natural nematicidal and nematocide comprising the same |
CN109820778A (en) * | 2019-02-20 | 2019-05-31 | 田朝晖 | A kind of hickory chick biofermentation bacterium solution composite skin care product and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
JP5480864B2 (en) | 2014-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5017697B2 (en) | Antibacterial agent | |
KR101467316B1 (en) | Oral cleansing composition fermented taraxacum extract-containing complex herbal extract | |
JP5480864B2 (en) | Antibacterial agent and oral composition containing the same | |
KR101841181B1 (en) | Toothpaste composition comprising herval extract | |
JP4948044B2 (en) | Plaque formation inhibitor or anti-cariogenic agent | |
JP4112730B2 (en) | Antibacterial agent for oral cavity | |
KR101046621B1 (en) | Antimicrobial composition comprising sun-dried salt and koji mulberry extract | |
JP4630416B2 (en) | Anti-caries, periodontal disease agent | |
CN107073053B (en) | Growth promoter for nonpathogenic resident bacteria in oral cavity, flora improving agent in oral cavity, and oral composition | |
KR102572961B1 (en) | Compositions for preventing, improving or treating periodontal disease containing dendropanax morbifera lev. extracts | |
JP5744985B2 (en) | Antibacterial agent | |
KR20120133135A (en) | Composition for Prevention or Treatment of Dental Caries Comprising Extract of Cannabis sativa | |
KR20140031512A (en) | Composition for treating oral disease and inhibiting halitosis comprising the extract of schizandra chinensis | |
KR102438800B1 (en) | Composition comtaining lactic acid fermented noni extract as active ingredient for prevention or treatment of oral disease | |
WO2022075481A1 (en) | Oral care composition comprising sweet potato-derived potato syrup or potato syrup supernatant | |
KR102537844B1 (en) | Composition with antibacterial, antioxidant, and anti-inflammatory activity containing ingredients converted to kimchi lactic acid bacteria and breast lactic acid bacteria in marigold extract | |
Galhotra et al. | Anticariogenic And Cariostatic Potential Of Components Of Diet: A Review. | |
JP7433125B2 (en) | Oral antibacterial agent | |
KR102546957B1 (en) | Anti-inflammatory and antibacterial composition comprising a Cedrela sinensis extract as an active ingredient | |
JP2005281224A (en) | Skin-whitening agent | |
JP7368858B2 (en) | Biofilm formation inhibitor | |
KR20130078526A (en) | Composition for inhibiting oral bacteria comprising the extract of ixeris dentata | |
Shafiei | In Vitro Study on the Effect of Plant Extract Mixture and Its Individual Constituents Towards Single-And Dual-Species Biofilms | |
KR20230046760A (en) | Composition for preventing biofilm formation comprising extract of vitidis viniferae caulis | |
KR20230046819A (en) | Composition for preventing biofilm formation comprising extract of vitidis viniferae caulis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20111027 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111027 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130327 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130619 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20130814 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130819 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130814 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140131 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140214 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5480864 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |